We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189 → 203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

0.19% less ownership

Funds ownership: 105.35% → 105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$121M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$83.1M
3
Ameriprise
Ameriprise
Minnesota
+$82.4M
4
Fidelity International
Fidelity International
Bermuda
+$58.7M
5
ACA
Avoro Capital Advisors
New York
+$31.3M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$345M
2
Artisan Partners
Artisan Partners
Wisconsin
-$187M
3
Brown Advisory
Brown Advisory
Maryland
-$27.9M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$18.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAM
201
Bellevue Asset Management
Washington
$2.04K – – –
JSAM
202
J. Safra Asset Management
New York
$1.5K +$1.5K +11 New
CFB
203
Cullen/Frost Bankers
Texas
$409 +$408 +3 New
FCM
204
Farallon Capital Management
California
– -$16.5M -109,000 Closed
ACM
205
Atika Capital Management
New York
– -$7.33M -48,500 Closed
CSS
206
Cubist Systematic Strategies
Connecticut
– -$5.09M -33,661 Closed
JFG
207
Jefferies Financial Group
New York
– -$3.65M -24,151 Closed
PCM
208
Penserra Capital Management
California
– -$2.93M -19,412 Closed
SCM
209
Superstring Capital Management
New York
– -$1.93M -12,754 Closed
GCP
210
GSA Capital Partners
United Kingdom
– -$992K -6,564 Closed
AI
211
AXS Investments
New York
– -$907K -6,000 Closed
FC
212
FORA Capital
Florida
– -$703K -4,649 Closed
TC
213
Torno Capital
Massachusetts
– -$680K -4,500 Closed
ACM
214
Aquatic Capital Management
Illinois
– -$650K -4,300 Closed
QT
215
Quantbot Technologies
New York
– -$590K -3,900 Closed
TSS
216
Two Sigma Securities
New York
– -$283K -1,875 Closed
PAM
217
Pinpoint Asset Management
Hong Kong
– -$257K -1,698 Closed
CWA
218
CM Wealth Advisors
Ohio
– -$228K -1,674 Closed
HA
219
HC Advisors
Georgia
– -$224K -1,479 Closed
PWP
220
Pursue Wealth Partners
California
– -$219K -1,451 Closed
HSBC Holdings
221
HSBC Holdings
United Kingdom
– -$219K -1,448 Closed
YIH
222
Y-Intercept (HK)
Hong Kong
– -$213K -1,406 Closed
PO
223
Private Ocean
California
– -$36.4K -241 Closed
EC
224
EntryPoint Capital
New York
– -$29.2K -193 Closed
EC
225
Elequin Capital
New York
– -$7.56K -50 Closed
6 7 8
9
10

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.